EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-SA 4.0

Androgen receptor inhibitors in treating prostate cancer

Ryan N Cole, Qinghua Fang, Kanako Matsuoka, Zhou Wang

Asian Journal of Andrology · 2025-03 · 27 (2) · 144-155

DOI: 10.4103/aja202494 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Asian Journal of Andrology, online erschienen am 19.11.2024. Verfasst von Ryan N Cole und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgens play an important role in prostate cancer development and progression. Androgen action is mediated through the androgen receptor (AR), a ligand-dependent DNA-binding transcription factor. AR is arguably the most important target for prostate cancer treatment. Current USA Food and Drug Administration (FDA)-approved AR inhibitors target the ligand-binding domain (LBD) and have exhibited efficacy in prostate cancer patients, particularly when used in combination with androgen deprivation therapy. Unfortunately, patients treated with the currently approved AR-targeting agents develop resistance and relapse with castration-resistant prostate cancer (CRPC). The major mechanism leading to CRPC involves reactivation of AR signaling mainly through AR gene amplification, mutation, and/or splice variants. To effectively inhibit the reactivated AR signaling, new approaches to target AR are being actively explored. These new approaches include novel small molecule inhibitors targeting various domains of AR and agents that can degrade AR. The present review provides a summary of the existing FDA-approved AR antagonists and the current development of some of the AR targeting agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen Receptor AntagonistsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleReceptors, AndrogenSignal Transduction

Substanzen

Androgen Receptor AntagonistsReceptors, Androgen

Autor:innen und Institutionen

  • Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
  • UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
  • Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Cole, R. N., Fang, Q., Matsuoka, K., & Wang, Z. (2025). Androgen receptor inhibitors in treating prostate cancer. Asian Journal of Andrology, 27(2), 144-155. https://doi.org/10.4103/aja202494

Vancouver

Cole RN, Fang Q, Matsuoka K, Wang Z. Androgen receptor inhibitors in treating prostate cancer. Asian Journal of Andrology. 2025;27(2):144-155. doi:10.4103/aja202494

BibTeX
@article{Cole2025,
  author = {Cole, Ryan N and Fang, Qinghua and Matsuoka, Kanako and Wang, Zhou},
  title = {Androgen receptor inhibitors in treating prostate cancer},
  journal = {Asian Journal of Andrology},
  year = {2025},
  volume = {27},
  number = {2},
  pages = {144--155},
  doi = {10.4103/aja202494}
}
Kostenlos starten →